Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T12:56:11.439Z.
Calculation as of: 2026-10-06T12:56:11.439Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PE RATIO
N/A
Market Cap
$84.75M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Conexeu Sciences Inc. (CNXU) | $83.49M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.00M | N/A | 8.03 | 8.03 | 8.03 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | N/A | 3.67 | 3.67 | 3.67 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 29.23 | 45.53 | 45.53 | 24.63 |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | N/A | N/A | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 115.25 | 46.83 | 44.28 | 282.12 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
